Oncoinvent ASA (OSE: ONCIN) a clinical stage radiopharmaceutical company
developing innovative treatments for solid cancers, invites for a presentation
of the top-line results from the Phase 1/2a clinical trial (RAD-18-002)
evaluating Radspherin® in patients with peritoneal metastases originating from
colorectal cancer.
A webcast will be held on June 18th 2025 at 13:00 CEST. A link to the webcast
will be available for everyone to view on www.oncoinvent.com. There will be a
possibility for Q&A through the MS Teams Webinar.
About Oncoinvent
Oncoinvent is a clinical-stage biotechnology company developing novel
radiopharmaceutical therapies against cancer. The lead product candidate,
Radspherin®, uses the alpha-emitting radionuclide radium-224, directly targeting
micro-metastases post-surgery, harnessing the benefits of modern
radiopharmaceuticals without the complexities of biological targeting.
Oncoinvent is investigating the safety and efficacy of Radspherin® in a clinical
development program in two indications. In addition to the currently finalized
phase 1/2a trial in colorectal cancer, one phase 1 trial and one randomized
phase 2 trial, both in ovarian cancer, are ongoing in the US, UK and Europe.
Preliminary clinical efficacy data are highly encouraging, and no serious
toxicity or safety concerns have been reported to date. The experienced
Oncoinvent team runs a state-of-the-art manufacturing facility to produce drug
products for clinical trials in Nydalen, Oslo. Oncoinvent is listed on the
Euronext Growth Oslo.
About Radspherin
Radspherin® is an investigational radiopharmaceutical designed for the local
treatment of cancer that has spread to body cavities. It consists of billions of
calcium carbonate microparticles containing the radioactive material radium-224.
The mode of action is the decay of radium-224 emitting alpha-particles, a highly
potent form of ionizing radiation. Radspherin® is investigated in ongoing
clinical studies to treat peritoneal carcinomatoses from ovarian and colorectal
cancer and it is administered intraperitoneally after surgical resection with
removal of all macroscopic tumors.
Forward-Looking Statements
All statements other than statements of historical facts contained in this press
release are forward-looking statements and are not a representation that
Oncoinvent's plans, estimates, or expectations will be achieved. These
forward-looking statements represent Oncoinvent's expectations as of the date of
this press release, and Oncoinvent disclaims any obligation to update the
forward-looking statements. These forward-looking statements are subject to
known and unknown risks and uncertainties that may cause actual results to
differ materially, including with respect to whether the results of clinical or
other studies will support the use of our product offerings, the impact of
results of such studies, our expectations of the reliability, accuracy and
performance of our tests, or of the benefits of our tests and product offerings
to patients, providers and payers.
For further information, please contact:
Øystein Soug, Chief Executive Officer
Email: soug@oncoinvent.com
Tore Kvam, Chief Financial Officer
Email: kvam@oncoinvent.com